Eli Lilly and Company (LLY)
Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.
“History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but there are some caveats
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)
Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched valuations and also the lowering of prices of Zepbound on LillyDirect. But there's much going on in favour of LLY too. 2026 could be good too, which is in line with the company's earlier resilience in the face of price cuts, which the company's outlook would clarify.
Eli Lilly: The Right Long-Term Strategy
Eli Lilly is positioned for a secular growth trajectory, leveraging its duopoly in diabetes and obesity therapies while investing heavily in pipeline diversification. LLY faces intensifying competition and looming patent expirations, but is proactively expanding into oral, triple-agonist, and novel biologic modalities to sustain long-term revenue. Valuation risk is high in the near term, yet the robust pipeline support a buy rating for long-term investors.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Dec 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher.
Eli Lilly reports positive Phase 3 trial results for obesity drug retatrutide
Eli Lilly and Co (NYSE:LLY) has reported positive topline results from its Phase 3 TRIUMPH-4 trial evaluating its obesity treatment retatrutide in adults with obesity and knee osteoarthritis. The investigational drug, a once-weekly injectable targeting GLP‑1, GIP, and glucagon receptors, is designed to regulate appetite and metabolism through multiple hormone pathways.
Eli Lilly's newest weight-loss drug relieved pain in patients with knee osteoarthritis
Eli Lilly's “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis in a Phase 3 trial.
Eli Lilly Reports Positive Results From Study of Weight Loss Drug
Eli Lilly's experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase three trial involving patients with obesity and knee osteoarthritis.
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy. The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment.
Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial
Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing the company's lead in the fast-growing market.
Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost Production
With demand for weight-loss drugs soaring and an agreement with the White House to produce more medicine in the U.S., Eli Lilly (LLY) is taking steps to boost its domestic output.
